Daily non-political popular news in brief.

Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms

Shire plc announced positive results of four studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term and two long-term phase 3 studies, presented at the American Psychiatric Association annual meeting, demonstrated GXR significantly improved all core symptoms of ADHD in children aged 6 to 17 years. GXR is the first selective alpha-2A-adrenoceptor agonist tested in well-controlled studies as an ADHD treatment.

Read more »

Keywords: investigational, nonstimulant, guanfacine, significantly, improved, child, adolescent, adhd, symptoms, symptom

« Previous | Next »

Similar news on "Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms":

1. Shire investigational drug (SPD465) designed to reduce ADHD symptoms for up to 16 hours
   10-31-2006 · EurekAlert!
   Shire announced that the investigational amphetamine compound SPD465 (triple-bead mixed amphetamine salts) improved Attention-Deficit/Hyperactivity Disorder symptoms in adults for up to 16 hours post-dose and had a generally well-tolerated safety profile consistent with currently marketed amphetamine products, according to the results of two phase 2 trials released at a meeting of child and adolescent psychiatrists in San Diego, California.
   Similar news · Read more »
   
2. Shire announces once-daily guanfacine extended release data in ADHD patients aged 6 to 17 years
   11-16-2006 · EurekAlert!
   Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) announced that once-daily doses of the investigational medication guanfacine extended release (GXR, also referred to as SPD503), a selective alpha-2A-adrenoceptor agonist, significantly improved symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 17 years when used as a monotherapy, according to phase 3 trial results presented at the 2006 US Psychiatric & Mental Health Congress. Two additional studies also released at the meeting report the pharmacokinetic profile of GXR.
   Similar news · Read more »
   
3. DAYTRANA (methylphenidate transdermal system) provides individualized ADHD symptom management
   10-27-2006 · EurekAlert!
   Shire's Attention Deficit Hyperactivity Disorder patch, DAYTRANA tm (methylphenidate transdermal system) has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when removed earlier than the recommended nine hours. The ability to remove the patch earlier allows physicians the opportunity to manage potential late-day side effects, such as lack of appetite or difficulty sleeping, according to phase 3b trial results reported at a scientific child and adolescent psychiatry meeting in San Diego.
   Similar news · Read more »
   
4. Lisdexamfetamine dimesylate in ADHD phase 3 data presented
   10-27-2006 · EurekAlert!
   Shire and New River Pharmaceuticals Inc. announce that their investigational ADHD treatment, lisdexamfetamine dimesylate, also known as NRP104 or LDX, yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 12 years who received six months of treatment in an open-label phase 3 study presented at a national meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
5. New drug reduces abdominal fat accumulation and improves lipids in HIV-infected patients
   12-05-2007 · EurekAlert!
   Treatment with an investigational drug that induces the release of growth hormone significantly improved the symptoms of HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection.
   Similar news · Read more »
   
6. Long-term 12-month safety data on ADHD patch DAYTRANA
   10-25-2007 · EurekAlert!
   Shire plc announced that DAYTRANA (methylphenidate transdermal system), the ADHD patch, provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years, according to data from a 12-month study presented today at a major scientific and educational meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
7. Dramatic hike forecast for ADHD drugs spend
   11-14-2007 · EurekAlert!
   The NHS is likely to face a ten-fold increase in the cost of drugs prescribed to children and adolescents with attention-deficit/hyperactivity disorder in the decade to 2012.The research, published in the online open access journal Child and Adolescent Psychiatry and Mental Health, modelled various scenarios to determine possible costs to the National Health Service in England and the statutory health insurance providers in Germany.
   Similar news · Read more »
   
8. Many adults with psychiatric disorders may also have undiagnosed ADHD
   10-27-2006 · EurekAlert!
   Shire announced today that many adults with a depressive disorder, bipolar disorder or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder, according to a longitudinal retrospective U.S. medical claims analysis presented at a medical meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
9. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
   11-15-2007 · EurekAlert!
   Tamiflu significantly reduces illness severity and duration in children one year and older, particularly if given within 24 hours of symptom onset, according to new data presented at the World Society for Pediatric Infectious Disease meeting in Bangkok Nov. 15-18. The antiviral Tamiflu was also shown to reduce theincidence of respiratory tract infections, ear infections and antibioticuse. In addition this season smaller child-sized Tamiflu capsules of 30 mg and 45 mg doses will be available to provide easier and more convenient dosing by parents.
   Similar news · Read more »
   
10. Shire analysis compares stimulant to nonstimulant ADHD medications in patients aged 8 to 15 years
    11-16-2006 · EurekAlert!
    Shire plc announced study results that suggested that stimulant medications such as Adderall XR (mixed salts of a single-entity amphetamine product) are significantly more effective than nonstimulant medications in the treatment of patients aged 8 to 15 years with Attention-Deficit/Hyperactivity Disorder. The study, a meta-analysis of 29 studies undertaken during the last 25 years with nearly 4,500 children with ADHD, was presented at the U.S. Psychiatric and Mental Health Congress.
    Similar news · Read more »